Syndax Pharmaceuticals, Inc. (SNDX) Dividend History

Company News

• Syndax Announces Participation in June Investor Conferences

  Syndax Pharmaceuticals announced that it will present data on its cancer therapies Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr) at the upcoming EHA 2025 conference.

  GlobeNewswire Inc.
• Syndax Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

  Syndax Pharmaceuticals reported strong initial sales of its cancer drug Revuforj and launched its chronic GVHD drug Niktimvo in the U.S. The company expects to submit a supplemental NDA for Revuforj in relapsed/refractory mNPM1 AML in 2Q25 and has a robust development strategy underway for both drugs.

  GlobeNewswire Inc.
• Syndax to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call and Webcast on March 3, 2025

  Syndax Pharmaceuticals, a commercial-stage biopharmaceutical company, will report its fourth quarter and full year 2024 financial results and provide a business update on March 3, 2025.

  GlobeNewswire Inc.
• Kuehn Law Encourages Investors of Syndax Pharmaceuticals, Inc. to Contact Law Firm

  Kuehn Law, a shareholder litigation law firm, is investigating potential self-dealing by officers and directors of Syndax Pharmaceuticals, Inc. (SNDX). Shareholders may be entitled to damages and corporate governance reforms.

  GlobeNewswire Inc.
• Pulmonary Fibrosis Clinical Trial Pipeline Appears Robust With 110+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

  The pulmonary fibrosis market is driven by the increasing prevalence of the disease, especially idiopathic pulmonary fibrosis, among the aging population. Innovations in drug development and diagnostics, favorable reimbursement policies, and greater awareness are fueling market growth. The pipeline appears robust with over 110 active players working on 120+ pipeline drugs.

  GlobeNewswire Inc.

  Featured Companies: CTNM SRPT TRVI